Myriad Genetics (MYGN) reported earnings on Tue 2 May 2017 (a/h)

** charts before earnings **

  

** charts after earnings **

 

Myriad Genetics beats by $0.03, beats on revs; guides Q4 EPS midpoint above consensus, revs above consensus:

• Reports Q3 (Mar) earnings of $0.27 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.24; revenues rose 3.4% year/year to $196.9 mln vs the $189.1 mln Capital IQ Consensus.
• Co issues guidance for Q4, sees EPS of $0.26-0.28, excluding non-recurring items, vs. $0.26 Capital IQ Consensus Estimate; sees Q4 revs of $192-194 mln vs. $188.50 mln Capital IQ Consensus Estimate.
• "Coupled with meaningful sequential volume growth in all of our major pipeline tests including GeneSight, Vectra DA, Prolaris, and EndoPredict, we believe we are rapidly approaching an important inflection in our business where our new products will drive accelerated revenue growth and profitability."